Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment

Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment

Abstract Zavegepant, a high‐affinity, selective, small‐molecule calcitonin gene‐related peptide (CGRP) receptor antagonist, is approved in the United States for acute treatment of migraine in adults. The effects of moderate hepatic impairment (8 participants with Child‐Pugh score 7-9 points) on the...

Full description

Saved in:
Bibliographic Details
Main Authors: Rajinder Bhardwaj (Author), Mary K. Donohue (Author), Jennifer Madonia (Author), Beth Morris (Author), Thomas C. Marbury (Author), Kyle T. Matschke (Author), Robert Croop (Author), Richard Bertz (Author), Jing Liu (Author)
Format: Book
Published: Wiley, 2024-07-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items